Urolithin A (UA) One of 4 Promising Agents 2024 by Brian Kennedy of NSU

#386

I tried some high dose UA and did not notice anything. I do notice other things such as Rapamycin.

2 Likes
#387

Iā€™m 3 weeks into a daily pomegranate regimen (arils + molasses +pomegranate peel powder) to see if i notice an improvement in my vo2 max. Im due to test in 5 weeks - so will keep you posted

2 Likes
#388

Same here.

1 Like
#389

Thanks. It will be encouraging if you are able to produce UA efficiently that way. I could not determine that I was so I switched to 1,000 mg UA/day. Iā€™m not sure about the expectations time line for VO2max change but the changes in my lower body muscular performance ā€“ back to a more youthful profile ā€“ took the full period of several months noted in the research. Initial cellular changes can be noted around six weeks as I recall.

2 Likes
#390

I purchased their capsules once early on and they sent me a third-party purity analysis. Of course, this does not certify that the capsules contain the full amount. They seemed legit.

2 Likes
#391

thank you ive decided to extend my experiment to 4 months based on your info. And also because Iā€™m now craving pomegranate!

Iā€™m taking these cravings as a positive sign that Iā€™m ā€œmetabotype Aā€ (able to convert all the punicalagins into urolithin -a)

2 Likes
#392

If you pattern is similar to mine, the change will catch you by surprise at an exercise session. Initially, you may write it off as just having a good day but it will persist.

2 Likes
#393

The Timing Reality Check: Urolithin A Rescues Aging Brain Biology, But Fails to Reverse Established Memory Loss

Urolithin A (UA) is a widely discussed postbiotic molecule known for triggering mitophagyā€”the cellular recycling of damaged mitochondria. While previous studies tout its benefits in Alzheimerā€™s models and muscle health, its efficacy in natural brain aging has remained uncertain. This new research investigates a critical clinical question: Does the timing of mitophagy activation matter for cognitive preservation?

The short answer is yes. The researchers found that while UA effectively prevents age-related cognitive decline when administered early, it fundamentally fails to reverse memory loss once significant mitochondrial and synaptic damage has already occurred.

The study employed two complementary mouse models to test early versus late intervention. For the late-stage model, 16-month-old naturally aging C57BL/6J miceā€”which already exhibit cognitive deficitsā€”were given UA for eight weeks. On a molecular level, the compound performed precisely as intended. It boosted ATP production, enhanced mitochondrial fusion proteins (Mfn1 and Mfn2), upregulated biogenesis markers like PGC-1a and Nrf2, and cleared pathological tau proteins (PHF-1) from hippocampal synapses. Yet, despite this impressive molecular repair, the mice showed no improvement in spatial or recognition memory. The biochemical rescue did not translate into functional cognitive recovery.

Conversely, the early intervention model utilized 5-month-old SAMP8 mice, a strain that undergoes accelerated aging and typically develops cognitive deficits by six months. When these mice received UA prior to the onset of memory loss, the results were striking. Hippocampal ATP levels surged by over 4-fold, toxic tau accumulation was blocked, and spatial learning was significantly preserved. Intriguingly, after this successful cellular stabilization, markers for mitophagy and biogenesis actually downregulated, suggesting the mitochondrial pool had reached a healthy homeostatic state that no longer required aggressive turnover.

These findings establish a critical reality check: metabolic therapies and mitophagy activators are not magic erasers for established neurodegeneration. Once synaptic networks are compromised, fixing the cellular power grid is insufficient. Compounds like UA must be utilized preventatively to protect brain healthspan.

Context:

1 Like